This site is intended for healthcare professionals

NDA for once-daily, oral relugolix combination tablet for the treatment of women with heavy menstrual bleeding associated with uterine fibroids accepted for review by the FDA.- Myovant Sciences

Read time: 1 mins
Last updated:16th Mar 2021
Published:18th Aug 2020
Condition: Uterine Fibroids
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest